Search

A study conducted by the National Autonomous University of Mexico (UNAM) in Leon focused on the development of a novel drug-loaded nanocarrier using titanium dioxide nanoparticles surface functionalized with 5-fluorouracil (5-FU) to enhance drug delivery for oral cancer treatment. The research aimed to address drug resistance issues commonly encountered during 5-FU chemotherapy. Results showed that the drug-loaded nanocarrier exhibited increased antitumor effects in oral cancer cell lines while minimizing cytotoxicity to human gingival fibroblasts. This study highlights the potential effectiveness of the TiO2/5-FU system in the tumor microenvironment. [Extracted from the article]

A patent application titled "APTAMER-siRNA FUSIONS" was published online by inventors HABIB, Nagy and VASCONCELOS, Luis. The application focuses on developing ribonucleic acid compounds for targeted delivery of therapeutic payloads to cancer cells, specifically pancreatic ductal adenocarcinoma (PDAC) with liver metastasis. The compounds consist of aptamers capable of binding to transferrin receptors and CCAAT/enhancer-binding protein b (C/EBPb) siRNA, offering potential advancements in cancer treatment. The patent application highlights the need for improved targeted therapeutic delivery methods in cancer treatment. [Extracted from the article]

A recent report from University Hospital Principe de Asturias in Madrid, Spain, highlights the continued importance of hydroxyurea in the treatment of sickle cell anemia. Hydroxyurea has been shown to reduce painful episodes, acute chest syndrome, and the need for transfusions and hospitalizations, ultimately leading to reduced morbidity and mortality. While alternative therapies are not yet approved in Europe, hydroxyurea remains a key therapy for both children and adults with sickle cell anemia, with caution advised during pregnancy and lactation. The study emphasizes the multifaceted mechanisms of action of hydroxyurea and its potential benefits in improving quality of life for patients with sickle cell anemia. [Extracted from the article]

A patent application by inventor Thomas H. Adams proposes a combination therapy for the treatment of Pan-Kras mutated cancers, focusing on the use of the CDK inhibitor milciclib in conjunction with other anticancer drugs. The application highlights the potential efficacy of milciclib in inhibiting cancer cell proliferation and suggests that combining it with a tyrosine kinase inhibitor could enhance anti-tumorigenic activity. The therapy targets KRAS mutations, particularly the prevalent KRAS G12C mutation in non-small cell lung cancer, aiming to address the unmet need for effective treatments in this patient population. [Extracted from the article]

A retrospective cohort study conducted at Tsinghua University in Beijing, China, compared the efficacy of a novel treatment regimen for advanced biliary tract cancer (BTC) with standard chemotherapy options. The study found that the novel regimen, which included hepatic artery infusion chemotherapy with mFOLFOX-HAIC, lenvatinib, and PD-1 inhibitors, demonstrated superior progression-free survival and overall survival compared to standard regimens. The research concluded that the new treatment appears to be safe and well-tolerated for advanced BTC patients. [Extracted from the article]

A study conducted at Tanta University in Egypt compared the efficacy of two chemotherapy regimens, docetaxel, cisplatin, and 5-fluorouracil (TPF) and gemcitabine/cisplatin (GP), in treating patients with locally advanced nasopharyngeal carcinoma (NPC). The research found that both regimens had a high overall response rate after induction chemotherapy, with the GP regimen showing lower rates of severe side effects compared to the TPF regimen. The study concluded that there was no significant difference in the 3-year disease-free survival and overall survival between the two protocols. [Extracted from the article]

A recent study conducted by researchers at the University of Iowa focused on the use of pharmacological ascorbate (P-AscH-) in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer. The study found that adding P-AscH- to the treatment regimen increased overall survival to 16 months compared to 8.3 months without it. Importantly, the addition of P-AscH- did not negatively impact quality of life or increase adverse events for patients. This research offers promising results for improving outcomes in patients with metastatic pancreatic cancer. [Extracted from the article]

A randomized phase 2 trial is being conducted to compare the effectiveness of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine, which work to produce normal blood cells and kill abnormal cells in the bone marrow. Iadademstat may stop tumor cell growth by blocking enzymes needed for cell growth. The trial aims to assess acute leukemia response rates, event-free survival, overall survival, and other outcomes in patients with MPNs. [Extracted from the article]

The article discusses an exploratory clinical trial, NCT06658951, evaluating the safety and preliminary efficacy of Anti-HER2 CAR-T cell injection in patients with HER2-positive advanced malignant solid tumors. The trial aims to determine the maximum tolerated dose of the injection and assess its safety and efficacy. The study is currently not recruiting participants, with a planned completion date of November 30, 2026, and is being conducted in China. The trial includes specific eligibility criteria and outcome measures to evaluate the effectiveness of the treatment. [Extracted from the article]

A clinical trial, NCT06662877, is being conducted to evaluate the efficacy of Anlotinib plus Nab-Paclitaxels and S-1 as a second-line treatment for advanced biliary tract cancer (BTC) compared to the standard FOLFOX regimen. The trial aims to improve treatment outcomes for patients with BTC, which has a low 5-year survival rate. The study will assess overall survival, progression-free survival, objective response rate, disease control rate, quality of life, and adverse events as primary and secondary outcome measures. The trial is set to start on November 25, 2024, with a primary completion date of September 1, 2029. [Extracted from the article]

Researchers from the Federal University Minas Gerais (UFMG) in Brazil conducted a study on sickle cell anemia, focusing on the effects of BCL11A gene variations on fetal hemoglobin induction in patients treated with hydroxyurea. The study involved 93 patients with sickle cell disease, and results showed an increase in hemoglobin, hematocrit, and fetal hemoglobin concentration during 18 months of hydroxyurea therapy. While the study did not find significant differences in fetal hemoglobin levels based on BCL11A gene variations, it suggested that these variations may partially explain the variability in response to hydroxyurea therapy. Replication studies with a larger sample size are recommended for further investigation. [Extracted from the article]

A report from Mazandaran University of Medical Sciences in Sari, Iran discusses the synthesis and characterization of mesoporous silicate nanoparticles with low generation polyamidoamine dendrimers for the delivery of 5-fluorouracil to cancer cells. The study aimed to provide targeted and controllable drug delivery using nanoparticles. The research found that the nanoparticles effectively regulated the encapsulation and release of 5-FU, offering pH-sensitive and sustained medication delivery. This research has been peer-reviewed and offers potential for effective drug delivery to cancer cells. [Extracted from the article]

A recent report from the University of Montreal discusses the challenges in managing psoriasis with methotrexate due to its low bioavailability and invasiveness. The study explores the use of microneedle patches for sustained delivery of methotrexate and phloretin, a safer alternative with antipsoriatic potential. The patches show promising results in terms of drug delivery efficiency and antipsoriatic efficacy, offering a viable alternative for long-term psoriasis management. This research provides valuable insights into potential new treatments for psoriasis, aiming to improve patient compliance and overall well-being. [Extracted from the article]

A research study conducted at Aristotle University of Thessaloniki in Greece focused on the association between SLC19A1 gene polymorphisms and regulatory miRNAs with methotrexate toxicity in children with Acute Lymphoblastic Leukemia (ALL). The study found a statistically significant correlation between the rs1131596 polymorphism and the development of methotrexate-induced hepatotoxicity in patients with ALL. Additionally, the presence of genotype TT of rs1131596 and genotype AA of rs56292801 in a patient increased the risk of severe hepatotoxicity. The study did not find significant associations between the studied polymorphisms and other side effects such as mucositis, nausea, emesis, diarrhea, neutropenia, skin rash, and infections. [Extracted from the article]

The article discusses a phase 1 clinical trial, NCT06654037, testing the safety and efficacy of abemaciclib in combination with 5-fluorouracil for treating metastatic, refractory colorectal cancer. Abemaciclib, a cyclin-dependent kinase inhibitor, and 5-fluorouracil, an antimetabolite, are being studied for their potential to inhibit tumor growth and kill cancer cells. The trial aims to determine the maximum tolerated dose, anti-tumor activity, pharmacodynamics, and pharmacokinetics of the combination therapy. The study is currently in the recruitment phase and aims to enroll 39 participants by December 1, 2026. [Extracted from the article]

The article discusses a study that explores the mechanisms of action of the drug decitabine in treating high-risk acute myeloid leukemia (AML). Using a multiomics approach, researchers found that RNA dynamics play a crucial role in promoting cellular sensitivity to DNA hypomethylation induced cell death by decitabine. The study highlights the importance of understanding cancer vulnerabilities and drug mechanisms to develop effective cancer therapies. The preprint has not yet undergone peer review. [Extracted from the article]

A recent report from the University of Campania highlights the potential of combining curcumin and methotrexate for the treatment of osteosarcomas. The study suggests that curcumin, known for its antioxidant and anti-cancer properties, can downregulate components of the Hedgehog signaling pathway involved in tumorigenesis, inhibiting cancer progression. By targeting this pathway, curcumin and methotrexate showed promising pro-apoptotic effects, reducing the adverse effects of current therapies. This research offers new insights into potential therapeutic strategies for osteosarcoma treatment. [Extracted from the article]

A recent study conducted at the Kalasalingam Academy of Research and Education in Krishnankoil, India, explored the combinatory effect of Gemcitabine and 5-fluorouracil (GE5F) in targeting breast cancer cells. The research highlighted that co-delivering these FDA-approved drugs can enhance biological activity by targeting different protein mechanisms simultaneously, potentially increasing efficacy in fighting breast cancer. The study utilized molecular dynamics simulations and chemoinformatics to investigate the structural stability, reactivity, and interactions of the GE5F adduct, showing promising results for future in vitro and in vivo experiments. [Extracted from the article]

A clinical trial, NCT06652412, is being conducted to study the effects of Ultrafractionated Radiotherapy and Comprehensive Geriatric Assessment (CGA) Guided systemic treatment on elderly or frail patients with inoperable localized colorectal cancer. Patients will be classified as Frail, Vulnerable, or Fit based on CGA results, with corresponding treatment plans. The primary endpoint is the complete response rate, with secondary endpoints including adverse effects, anal preservation rate, and survival. The trial aims to provide valuable insights into the treatment of colorectal cancer in older or frail patients. [Extracted from the article]

Researchers from the University of Florida Research Foundation Inc. have submitted a patent application for a method that involves characterizing subjects with cancer, particularly leukemia, based on their genotype scores. The method aims to personalize treatment plans by administering cytarabine at tailored dosages according to the subject's genetic makeup. This approach could potentially improve outcomes for individuals with leukemia, including pediatric patients, by optimizing therapy augmentation. The patent application outlines specific SNP locations and genotype scoring methods to guide personalized therapy decisions in acute myeloid leukemia (AML) cases. [Extracted from the article]

Researchers from the Federal University of the Amazon conducted a study on sickle cell anemia patients treated with hydroxyurea to evaluate the effect of therapy on inflammatory cytokines. The study included 214 SCA patients and 240 healthy controls, with females being predominant in patients and males in controls. Plasma concentrations of cytokines were higher in patients, and specific genetic variations were associated with the disease and treatment outcomes. The research suggests that analyzing inflammatory genes could help understand the variability in sickle cell anemia patients and their response to hydroxyurea therapy. [Extracted from the article]

A recent study conducted in Dammam, Saudi Arabia, focused on the prescribing patterns of Hydroxyurea (HU) in sickle cell disease (SCD) patients and its association with co-prescribed medications used to manage SCD complications. The study included 2816 SCD patients, with a 56% prevalence of HU prescription, more common in young age groups and males. Findings suggested that patients prescribed HU were more likely to have certain medications co-prescribed, raising concerns about compliance and adherence to HU therapy, particularly among young female SCD patients. The study emphasizes the importance of early health education to improve the success rate of HU therapy. [Extracted from the article]

Researchers at the Georgia Institute of Technology conducted a study on sickle cell anemia, a blood disorder that causes severe complications. The study focused on the effects of hydroxyurea treatment on pathways altered during vaso-occlusive events in sickle cell disease. Findings showed that treatment with hydroxyurea can reduce the severity of vaso-occlusive events by downregulating inflammatory pathways, offering benefits beyond increasing fetal hemoglobin levels. The research provides insights into potential therapeutic approaches for managing sickle cell disease. [Extracted from the article]

Researchers from the Icahn School of Medicine at Mount Sinai have found that new treatments and guidelines for sickle cell disease (SCD) have improved patient outcomes, with over 90% of SCD patients living into adulthood and many living past 50 years of age. The study focused on SCD patients with and without cerebrovascular disease (CVD) and found that those with CVD were more likely to have certain comorbidities and receive specific treatments like blood transfusions and hydroxyurea. The research suggests that there may be an underutilization of treatment options among SCD patients with CVD, highlighting the need for further investigation and efforts to increase the use of standard treatments. [Extracted from the article]

Researchers from the University of Turin conducted a study on Hydroxyurea (HU) pharmacokinetics in patients with sickle cell disease (SCD). The study aimed to optimize dosing strategies and improve treatment efficacy by analyzing HU plasma concentrations at various time points. Results showed a positive correlation between HU plasma concentration and Body Mass Index (BMI) and dose per Body Surface Area (BSA). The research concluded that careful monitoring and individualized dosing of HU are crucial for reducing disease complications and improving patients' quality of life. [Extracted from the article]

Researchers from Amsterdam University Medical Center conducted a study on the cost-effectiveness and cost-utility of mercaptopurine treatment compared to a placebo in ulcerative colitis patients. The study found that mercaptopurine treatment was cost-effective from a societal perspective, with higher costs per additional responder and quality-adjusted life-year gained compared to the placebo. The research was supported by the Netherlands Organization for Health Research and Development and was published in the United European Gastroenterology Journal. [Extracted from the article]

A clinical trial, NCT06652139, is being conducted at Ruijin Hospital to evaluate the efficacy and safety of selinexor combined with BEAM as a preconditioning regimen for autologous stem cell transplantation in patients with relapsed and refractory diffuse large B-cell lymphoma with MYC positivity. The trial involves 82 patients who will be randomly assigned to receive either the experimental selinexor combined with BEAM regimen or the control BEAM regimen before undergoing ASCT therapy. The primary outcome measures include progression-free survival, overall survival, complete remission rate, time of hematopoietic reconstruction, and transplantation-related adverse reactions. [Extracted from the article]

The article discusses a Phase Ib/II clinical study (NCT06646055) evaluating the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as a first-line treatment for metastatic pancreatic cancer. The trial includes stage IV pancreatic cancer patients with an ECOG performance status of 0-1. The study aims to assess the frequency of adverse events, overall response rate, pharmacokinetics, anti-drug antibodies, progression-free survival, overall survival, disease control rate, duration of response, and time to response. [Extracted from the article]

Researchers from Mazandaran University of Medical Sciences conducted a study on the impact of glutamine mouthwash in preventing mucositis in children with acute lymphoblastic leukemia undergoing high-dose methotrexate therapy. The randomized clinical trial included 45 patients, with the intervention group receiving glutamine mouthwash and the control group receiving a placebo. The study found that glutamine mouthwash significantly reduced the incidence of nausea and vomiting, and up to 95% of patients were free from mucositis by the seventh day post-chemotherapy. The research was published in the Middle East Journal of Cancer. [Extracted from the article]

A recent study conducted at Al-Azhar University in Cairo, Egypt, explored the effectiveness and safety of using 5-Fluorouracil (5FU) as an adjuvant therapy for treating vitiligo. The meta-analysis of 10 studies involving 302 patients found that the combination of 5FU with microneedling showed superior efficacy in achieving over 75% repigmentation compared to other treatments. The research concluded that 5FU as an adjuvant treatment for vitiligo was more effective in achieving significant repigmentation rates. [Extracted from the article]

Researchers at Colorado State University have developed an alternative method to study changes during the DNA replication process using genetically modified yeast, offering a clearer understanding of cell cycle arrest. The study focuses on hydroxyurea, a chemotherapy drug used to treat cancer and in research settings to study DNA replication. The team found that hydroxyurea creates damaging reactive oxygen species in cells, leading them to develop a less toxic and reversible alternative using genetically engineered yeast cells. This new approach could significantly impact research on cell arrest, with plans to transfer the technique to human cells in the future. [Extracted from the article]

A recent study from the University of Foggia in Italy examined the use of methotrexate and mifepristone as a conservative treatment for cesarean scar pregnancy (CSP). The study found that this combination treatment can be effective, especially when certain conditions are met, such as low levels of beta human chorionic gonadotropin and a small gestational sac. The researchers suggest that individualized management and treatment based on clinical factors and patient preferences are crucial. This research provides valuable insights into the management of CSP and offers a potential alternative first-line treatment option. [Extracted from the article]

A report from the University Medical Center Utrecht in the Netherlands discusses the real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children under 12 years old. The study focused on the effectiveness, safety, and adherence of dupilumab, cyclosporine, and methotrexate over a 2-year period. Results showed that dupilumab had better outcomes and higher adherence compared to cyclosporine and methotrexate. The study did not involve randomization, placebos, or specified dosages. [Extracted from the article]

A recent study conducted by researchers at Boston University focused on the effectiveness of leflunomide as an adjunctive therapy with anti-tumor necrosis factor (anti-TNF) agents in pediatric patients with uveitis who cannot tolerate methotrexate. The study included five children who showed decreased side effects and lower flare rates when methotrexate was replaced with leflunomide in conjunction with anti-TNF therapy. The research concluded that leflunomide was well tolerated and effective in maintaining uveitis quiescence in pediatric patients who do not tolerate methotrexate. [Extracted from the article]

A study conducted at the University Medical Center Groningen in the Netherlands examined the drug survival rates of dupilumab, methotrexate, and cyclosporine A in pediatric patients with atopic dermatitis. The research found that dupilumab had the highest overall drug survival rates at 1, 2, and 3 years, followed by methotrexate, with cyclosporine A having the lowest rates. Factors such as ineffectiveness and adverse effects were identified as reasons for drug discontinuation, with certain age groups and treatments being associated with higher risks. This study aims to provide insights into the effectiveness, safety, and tolerability of systemic treatments for pediatric patients with atopic dermatitis to optimize patient outcomes. [Extracted from the article]

The article explores the impact of capecitabine therapy on the gut microbiota of colorectal cancer patients through metagenomic analysis. The study found that capecitabine treatment altered microbial composition, leading to an increase in menaquinol biosynthesis genes which protected bacteria from drug toxicity. Machine learning models were used to predict drug toxicities based on microbiome profiling. The findings suggest that microbial vitamin biosynthesis may play a chemoprotective role, with implications for reducing drug toxicities in cancer patients. [Extracted from the article]

The article discusses a clinical trial, NCT06643962, focusing on the efficacy and safety of combining Venetoclax with intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia and lower early peripheral blast clearance rates after standard induction therapy. The trial aims to evaluate outcomes such as complete remission rates, event-free survival, relapse-free survival, and overall survival. Eligibility criteria include age between 18-70, fitness for intensive chemotherapy, and specific health parameters. The study is not yet recruiting, with an enrollment target of 83 participants and a completion date of October 31, 2027. [Extracted from the article]

A study conducted in Cairo, Egypt, examined the efficacy of endobronchial intratumoral injection of 5-Fluorouracil as a chemotherapeutic agent in palliative care for patients with inoperable nonsmall-cell lung cancer (NSCLC). The research concluded that this treatment approach was not effective in improving outcomes for patients with advanced malignant endobronchial NSCLC. The study involved 30 patients and found no significant difference in tumor response between those who received systemic chemotherapy alone and those who received systemic chemotherapy along with local chemotherapy using 5-fluorouracil. The findings were published in The Egyptian Journal of Chest Diseases and Tuberculosis. [Extracted from the article]

The article discusses a study that utilized Molecular Pixelation (MPX) to analyze changes in the cell surface proteome of leukemia cells treated with fludarabine, a chemotherapeutic agent. The research focused on the ETV6::RUNX1 acute lymphoblastic leukemia (ALL) cell line, Reh, and identified alterations in protein abundance, polarity, and colocalization post-treatment. The study highlighted the potential therapeutic implications of certain proteins, such as CD82 and CD53, in chemotherapy resistance. This research showcases the value of spatially resolved single-cell proteomics in uncovering subtle cellular responses. [Extracted from the article]

A study conducted at Sun Yat-sen University in Guangzhou, China, explored the effectiveness of capecitabine plus PD-1 antibody as maintenance therapy in advanced or metastatic gastric cancer patients who had received oxaliplatin-based chemotherapy. The research found that patients maintained with capecitabine plus PD-1 antibody had significantly longer progression-free survival and overall survival compared to those on capecitabine monotherapy. Subgroup analysis indicated that patients with high expression of PD-L1 or low levels of CXCL12 benefited more from the maintenance therapy. This study provides valuable insights into potential treatment options for gastric cancer patients. [Extracted from the article]

A recent study from the University of Gothenburg explores the impact of methotrexate on rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). The research found that methotrexate treatment can lead to the release of granulocyte-macrophage colony-stimulating factor (GM-CSF) from RA-FLS through autocrine interleukin-1 signaling, potentially contributing to persistent synovitis. This study sheds light on the complex mechanisms underlying rheumatoid arthritis and the effects of methotrexate therapy. [Extracted from the article]

Researchers at Tehran University of Medical Sciences conducted a study to evaluate the efficacy of different wipes in sampling the antineoplastic drug 5-fluorouracil from various surfaces. The study found that alcohol pads were the most effective in collecting and extracting the drug, especially from hard, smooth surfaces like stainless steel and ceramic. These findings could lead to improved sampling methods and potentially reduce occupational exposure to antineoplastic drugs. Further research on different wipes and extraction parameters may refine drug analysis techniques in the future. [Extracted from the article]

The article discusses the development of a novel bone-targeted prodrug, 1102-39, aimed at enhancing the therapeutic effects of methotrexate (MTX) within bone tissues while minimizing systemic toxicity. In vitro tests showed a 10-fold reduction in cytotoxicity compared to standard MTX, with promising antitumor effects on orthotopic osteosarcoma in rodents. The research highlights the potential of designing molecules for selective therapy in bone tissue using bisphosphonate vectors for delivering active compounds. The 1102-39 molecule demonstrates strong affinity for hydroxyapatite and gradual release of MTX, improving the safety and efficacy of bone-specific treatments for tumors and inflammation. [Extracted from the article]

Researchers at Huazhong University of Science and Technology have introduced a new laboratory experiment focusing on supramolecular research, combining the chemotherapeutic agent gemcitabine with the antiviral drug acyclovir and proteasome inhibitor bortezomib. This experiment aims to illustrate the concepts of H-bonding interaction and boronic ester bonds using NMR and mass spectrometry technologies. The study emphasizes the importance of incorporating constitutional dynamic chemistry (CDC) into chemistry education to enhance students' understanding of complex matter chemistry. The research was funded by the National Natural Science Foundation of China and the National Key R&D Program of China, and has been peer-reviewed. [Extracted from the article]

A recent study conducted by a researcher at Gachon University in South Korea explored the effects of dietary yeast b-1,3/1,6-D-glucan on immunomodulation in RAW 264.7 cells and methotrexate-treated rat models. The study found that the yeast-derived b-1,3/1,6-D-glucan demonstrated significant immunomodulatory effects, including repairing immune organ damage and enhancing immune responses. The research suggests that further investigation into the potential of b-1,3/1,6-D-glucan as an immunomodulatory nutraceutical is warranted, particularly for patients with rheumatoid arthritis undergoing long-term methotrexate therapy. [Extracted from the article]

A clinical trial, NCT06640582, is investigating the safety and efficacy of combining autologous tumor-infiltrating lymphocytes (TIL) therapy with Pembrolizumab immunotherapy for patients with advanced brain cancer, including gliomas and meningiomas. This personalized treatment approach aims to utilize the patient's own immune cells to combat cancer, similar to the success seen in treating melanoma. The trial's primary endpoint is to determine the objective response rate (ORR), with secondary endpoints including disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This study offers a novel treatment option for patients with limited therapeutic alternatives. [Extracted from the article]

A patent issued by Johns Hopkins University discusses a method to increase the therapeutic efficiency of oncolytic bacterial therapy for solid tumors. The patent focuses on using immunoregulatory compounds, such as hydroxyurea, to suppress neutrophils before administering anaerobic bacteria to treat tumors. This approach aims to enhance tumor clearance and reduce treatment-related toxicities, addressing the challenges faced in current cancer therapies. The patent provides detailed methods and compounds for treating various types of solid tumors, emphasizing the importance of neutrophil suppression in improving the efficacy of oncolytic bacterial therapy. [Extracted from the article]

The article discusses a clinical trial, NCT06643585, comparing Trastuzumab-Deruxtecan to standard therapy in HER2-positive or HER2-low early breast cancer patients with molecular relapse. The trial aims to evaluate ctDNA clearance rate after 12 months between the two treatment arms. The study is interventional, phase III, and randomized, with recruitment not yet started and an enrollment target of 180 participants by December 1, 2031. The eligibility criteria include specific age ranges, breast cancer diagnosis, and compliance with study procedures, while exclusion criteria involve certain medical conditions and history of specific treatments. [Extracted from the article]

A clinical trial, NCT06643000, aims to evaluate the efficacy of high-dose furmonertinib combined with bevacizumab and pemetrexed in treating non-small cell lung cancer (NSCLC) with leptomeningeal metastasis and EGFR mutations. The study will assess overall survival, time to treatment failure, leptomeningeal objective response rate, and clinical response rate, as well as quality of life and safety. The trial targets 60 eligible NSCLC patients with EGFR mutations and leptomeningeal metastasis, using a combination of furmonertinib, bevacizumab, and pemetrexed administered every 3 weeks. [Extracted from the article]